首页> 外国专利> Antibodies against CD154 whose variable domain of the heavy chain has CDR1 and CDr3 specific sequence of DNA that encodes, Pharmaceutical composition containing such Antibodies,Useful for treating Diseases mediated by CD154, as the rejection of allografts.

Antibodies against CD154 whose variable domain of the heavy chain has CDR1 and CDr3 specific sequence of DNA that encodes, Pharmaceutical composition containing such Antibodies,Useful for treating Diseases mediated by CD154, as the rejection of allografts.

机译:针对CD154的抗体,其重链可变区具有CDR1和CDr3编码的DNA特异性序列,含有这种抗体的药物组合物,可用于治疗CD154介导的疾病,如同种异体移植的排斥反应。

摘要

Provides a link of CD154 Molecule, in particular an Antibody to human CD154, especially a Human Antibody to human CD154,Where the CDRs of amino acids as defined,To be used and the Treatment or prevention of diseases or Disorders where it is therapeutically beneficial Modulation, and / or interference with,Cd154o inhibition of CD40 CD154 interactions;.
机译:提供CD154分子的链接,尤其是人CD154的抗体,尤其是人CD154的人抗体,其中所定义的氨基酸CDR在治疗上有益的用途以及治疗或预防疾病或疾病的调节和/或干扰Cd154o抑制CD40,CD154相互作用;

著录项

  • 公开/公告号CL2001000584A1

    专利类型

  • 公开/公告日2001-12-18

    原文格式PDF

  • 申请/专利权人 NOVARTIS AG;

    申请/专利号CL2001000584

  • 发明设计人 DI PADOVA FRANCO E.;SCHULER WALTER;

    申请日2001-03-15

  • 分类号A61K39/395;A61P37/06;C07K16/28;C12N15/13;

  • 国家 CL

  • 入库时间 2022-08-22 00:45:53

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号